Abstract P5-15-02: Safety of letrozole-gonadotropin controlled ovarian stimulation protocol in women with breast cancer undergoing fertility preservation before or after tumor resection via embryo or oocyte cryopreservation: A prospective cohort study

2015 ◽  
Author(s):  
Kutluk Oktay ◽  
Jayeon Kim ◽  
Giuliano Bedoschi ◽  
Volkan Turan
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Fertility Preservation ◽  
Prospective Cohort Study ◽  
Ovarian Stimulation ◽  
Prospective Cohort ◽  
Tumor Resection ◽  
Controlled Ovarian Stimulation ◽  
Oocyte Cryopreservation ◽  
Stimulation Protocol

scholarly journals Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Philip D. Poorvu ◽  
Jiani Hu ◽  
Yue Zheng ◽  
Shari I. Gelber ◽  
Kathryn J. Ruddy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Fertility Preservation ◽  
Prospective Cohort Study ◽  
Young Women ◽  
Prospective Cohort ◽  
Ovarian Function ◽  
Future Research ◽  
Normal Body Mass Index ◽  
Clinical Trial Registration

AbstractYoung women with breast cancer experience unique treatment and survivorship issues centering on treatment-related amenorrhea (TRA), including fertility preservation and management of ovarian function as endocrine therapy. The Young Women’s Breast Cancer Study (YWS) is a multi-center, prospective cohort study of women diagnosed at age ≤40, enrolled from 2006 to 2016. Menstrual outcomes were self-reported on serial surveys. We evaluated factors associated with TRA using logistic regression. One year post-diagnosis, 286/789 (36.2%) experienced TRA, yet most resumed menses (2-year TRA: 120/699; 17.2%). Features associated with 1-year TRA included older age (OR≤30vs36-40 = 0.29 (0.17–0.48), OR31-35vs36-40 = 0.67 (0.46–0.94), p = 0.02); normal body mass index (BMI) (OR≥25vs18.5-24. =0.59 (0.41–0.83), p < 0.01); chemotherapy (ORchemo vs no chemo = 5.55 (3.60–8.82), p < 0.01); and tamoxifen (OR = 1.55 (1.11–2.16), p = 0.01). TRA rates were similar across most standard regimens (docetaxel/carboplatin/trastuzumab +/− pertuzumab: 55.6%; docetaxel/cyclophosphamide +/− trastuzumab/pertuzumab: 41.8%; doxorubicin/cyclophosphamide/paclitaxel +/− trastuzumab/pertuzumab: 44.1%; but numerically lower with AC alone (25%) or paclitaxel/trastuzumab (11.1%). Among young women with breast cancer, lower BMI appears to be an independent predictor of TRA. This finding has important implications for interpretation of prior studies, future research, and patient care in our increasingly obese population. Additionally, these data describe TRA associated with use of docetaxel/cyclophosphamide, which is increasingly being used in lieu of anthracycline-containing regimens. Collectively, these data can be used to inform use of fertility preservation strategies for women who need to undergo treatment as well as the potential need for ovarian suppression following modern chemotherapy for young women with estrogen-receptor-positive breast cancer.Clinical trial registration: www.clinicaltrials.gov, NCT01468246.

Cynical distrust increases breast cancer risk: Evidence from a prospective cohort study

2002 ◽  
Author(s):  
A. R. Aro ◽  
H. J. de Koning ◽  
K. Vehkalahti ◽  
P. Absetz ◽  
M. Schreck ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Prospective Cohort Study ◽  
Prospective Cohort

scholarly journals Rate of rebound in follicle growth after cessation of ovarian stimulation in initial non‐responders: a prospective cohort study

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Norbert Gleicher ◽  
Andrea Weghofer ◽  
Sarah K. Darmon ◽  
David H. Barad
Keyword(s):  
Cohort Study ◽  
Prospective Cohort Study ◽  
Ovarian Stimulation ◽  
Prospective Cohort ◽  
Follicle Growth ◽  
Gonadotropin Stimulation ◽  
Reported Study ◽  
Complete Failure ◽  
Incremental Step ◽  
Autologous Oocytes

AbstractPreviously anecdotally observed rebounds in follicle growth after interruption of exogenous gonadotropins in absolute non-responders were the impetus for here reported study. In a prospective cohort study, we investigated 49 consecutive patients, absolutely unresponsive to maximal exogenous gonadotropin stimulation, for a so-called rebound response to ovarian stimulation. A rebound response was defined as follicle growth following complete withdrawal of exogenous gonadotropin stimulation after complete failure to respond to maximal gonadotropin stimulation over up to 5–7 days. Median age of study patients was 40.5 ± 5.1 years (range 23–52). Women with and without rebound did not differ significantly (40.0 ± 6.0 vs. 41.0 ± 7.0 years, P = 0.41), with 24 (49.0%) recording a rebound and 25 (51.0%) not. Among the former, 21 (87.5%) reached retrieval of 1–3 oocytes and 15 (30.6%) reached embryo transfer. A successful rebound in almost half of prior non-responders was an unsuspected response rate, as was retrieval of 1–3 oocytes in over half of rebounding patients. Attempting rebounds may, thus, represent another incremental step in very poor prognosis patients before giving up on utilization of autologous oocytes. Here presented findings support further investigations into the underlying physiology leading to such an unexpectedly high rebound rate.

scholarly journals The INTREST registry: protocol of a multicenter prospective cohort study of predictors of women’s response to integrative breast cancer treatment

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Heidemarie Haller ◽  
Petra Voiß ◽  
Holger Cramer ◽  
Anna Paul ◽  
Mattea Reinisch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Cohort Study ◽  
Cancer Treatment ◽  
Prospective Cohort Study ◽  
Cancer Care ◽  
Prospective Cohort ◽  
Breast Cancer Treatment ◽  
Cancer Data ◽  
Patient Reported

Abstract Background Cancer registries usually assess data of conventional treatments and/or patient survival. Beyond that, little is known about the influence of other predictors of treatment response related to the use of complementary therapies (CM) and lifestyle factors affecting patients’ quality and quantity of life. Methods INTREST is a prospective cohort study collecting register data at multiple German certified cancer centers, which provide individualized, integrative, in- and outpatient breast cancer care. Patient-reported outcomes and clinical cancer data of anticipated N = 715 women with pTNM stage I-III breast cancer are collected using standardized case report forms at the time of diagnosis, after completing neo−/adjuvant chemotherapy, after completing adjuvant therapy (with the exception of endocrine therapy) as well as 1, 2, 5, and 10 years after baseline. Endpoints for multivariable prediction models are quality of life, fatigue, treatment adherence, and progression-based outcomes/survival. Predictors include the study center, sociodemographic characteristics, histologic cancer and comorbidity data, performance status, stress perception, depression, anxiety, sleep quality, spirituality, social support, physical activity, diet behavior, type of conventional treatments, use of and belief in CM treatments, and participation in a clinical trial. Safety is recorded following the Common Terminology Criteria for Adverse Events. Discussion This trial is currently recruiting participants. Future analyses will allow to identify predictors of short- and long-term response to integrative breast cancer treatment in women, which, in turn, may improve cancer care as well as quality and quantity of life with cancer. Trial registration German Clinical Trial Register DRKS00014852. Retrospectively registered at July 4th, 2018.

Sign in / Sign up

Export Citation Format

Share Document